NOS3 and diastolic heart failure: Also, the development of eNOS enhancers (by upregulation of eNOS mRNA and protein), despite highly promising preclinical data of AVE9488 on improvement of left ventricular remodeling in experimental MI [243] and AVE3085 on improvement of diastolic heart failure in rats [244], did so far not result in a new clinical therapy.